Innate lymphoid cell composition associates with COVID‐19 disease severity. Issue 12 (14th December 2020)

• Record Type: Journal Article
• Authors: García, Marina; Kokkinou, Efthymia; Carrasco García, Anna; Parrot, Tiphaine; Palma Medina, Laura M; Maleki, Kimia T; Christ, Wanda; Varnaitė, Renata; Filipovic, Iva; Ljunggren, Hans‐Gustaf; Björkström, Niklas K; Folkesson, Elin; Rooyackers, Olav; Eriksson, Lars I; Sönnerborg, Anders; Aleman, Soo; Strålin, Kristoffer; Gredmark‐Russ, Sara; Klingström, Jonas; Mjösberg, Jenny
• Is Part Of: Clinical & translational immunology. Volume 9:Issue 12(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-12-14
• Subjects: coronavirus -- COVID‐19 -- immune response -- innate lymphoid cells -- respiratory viral infection -- SARS‐CoV‐2; Immunologic diseases -- Periodicals; Immunology -- Periodicals; Clinical medicine -- Periodicals; Immune System Diseases -- therapy; Immunotherapy; Immunologic Factors -- therapeutic use; Translational Medical Research; Molecular Targeted Therapy; Clinical medicine; Immunologic diseases; Immunology; Periodicals; Periodicals; Fulltext; Internet Resources; Periodicals; 616.079
• DOI: 10.1002/cti2.1224
• Languages: English
• ISSNs: 2050-0068

Abstract

Abstract: Objectives: The role of innate lymphoid cells (ILCs) in coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), is unknown. Understanding the immune response in COVID‐19 could contribute to unravel the pathogenesis and identification of treatment targets. Here, we describe the phenotypic landscape of circulating ILCs in COVID‐19 patients and identified ILC phenotypes correlated to serum biomarkers, clinical markers and laboratory parameters relevant in COVID‐19. Methods: Blood samples collected from moderately ( n = 11) and severely ill ( n = 12) COVID‐19 patients, as well as healthy control donors ( n = 16), were analysed with 18‐parameter flow cytometry. Using supervised and unsupervised approaches, we examined the ILC activation status and homing profile. Clinical and laboratory parameters were obtained from all COVID‐19 patients, and serum biomarkers were analysed with multiplex immunoassays. Results: Innate lymphoid cells were largely depleted from the circulation of COVID‐19 patients compared with healthy controls. Remaining circulating ILCs revealed decreased frequencies of ILC2 in severe COVID‐19, with a concomitant decrease of ILC precursors (ILCp) in all patients, compared with controls. ILC2 and ILCp showed an activated phenotype with increased CD69 expression, whereas expression levels of the chemokine receptors CXCR3 and CCR4 were significantly altered in ILC2 and ILCp, and ILC1, respectively. The activated ILC profile of COVID‐19 patients was associated with soluble inflammatory markers, while frequencies of ILC subsets were correlated with laboratory parameters that reflect the disease severity. Conclusion: This study provides insights into the potential role of ILCs in immune responses against SARS‐CoV‐2, particularly linked to the severity of COVID‐19. Abstract : In this study, we found that circulating innate lymphoid cells (ILCs) are reduced in COVID‐19 patients. Severely diseased patients display decreased frequencies of ILC2 compared to moderate COVID‐19 patients and healthy donors, whereas ILC precursors are found decreased in all patients. The remaining circulating ILCs in COVID‐19 patients show a dysregulated expression of activation and migration markers, with an activated profile that associates with soluble inflammatory markers. Moreover, frequencies of ILC subsets correlate with laboratory parameters that reflect the disease severity.